Roche Hopes its Dx Can Help Monitor Cox-2 Patients for Cardiac Side Effects | GenomeWeb

Roche Diagnostics hopes that a cardiac prognostic test it currently sells can help identify patients at risk for adverse reactions to cox-2 inhibitors, CEO Heino von Prondzynski said during a conference call with investors this week.

"We … expect to have an opportunity for cox-2 inhibitor patient stratification" with the diagnostic, which looks for the protein NT-proBNP, von Prondzynski said during a section of the call devoted to clinical immunodiagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.